River­Vest off to the races with $275M to in­vest in ear­ly-stage biotech

5 years ago
Financing

Covid-19 roundup: In­dia halts As­traZeneca vac­cine ex­ports as in-coun­try cas­es rise — re­port

5 years ago
Coronavirus

Fol­low­ing the flow of the biotech in­dus­try, La­va heads to Nas­daq with a gam­ma delta T cell promise

5 years ago
Financing

FDA adds Guil­lain-Bar­ré syn­drome warn­ing to Glax­o­SmithK­line’s shin­gles vac­cine

5 years ago
Pharma
FDA+

T cell ther­a­py play­er Lyell pre­pares to open $65M man­u­fac­tur­ing fa­cil­i­ty in the Seat­tle area

5 years ago
Manufacturing

Neu­ro up­start launch­es out of RA Cap­i­tal’s low-pro­file in­cu­ba­tor with Big Phar­ma vets, clin­i­cal drugs and $80M

5 years ago
Financing
Startups

Un­der fire, As­traZeneca hus­tles out a pri­ma­ry cut of the num­bers for its Covid-19 vac­cine sup­port­ing pos­i­tive ...

5 years ago
R&D
Coronavirus

Mon­cef Slaoui of­fers his 'deep re­gret' over sex­u­al ha­rass­ment charge — while get­ting the boot from biotech posts

5 years ago
People

'Pro­tein print­ing' Ab­Sci se­cures $125M crossover as it ex­pands syn­thet­ic bi­ol­o­gy am­bi­tions

5 years ago
Financing

Te­va sees room for growth with FDA com­mu­ni­ca­tions and com­plex gener­ics, COO says

5 years ago
Pharma
FDA+

In a first for up­start syn­thet­ic bi­ol­o­gy field, Zymer­gen files for $100M IPO

5 years ago
Financing

Mer­ck­'s big C-suite shuf­fle con­tin­ues as Car­o­line Litch­field is tapped as new CFO

5 years ago
People

My­ovant adds re­l­u­golix da­ta in uter­ine fi­broids ahead of June PDU­FA; Mubadala teams up with UK for $1B+ fund

5 years ago
News Briefing

Glax­o­SmithK­line fires Mon­cef Slaoui as Gal­vani chair af­ter on­go­ing probe sub­stan­ti­ates sex­u­al ha­rass­ment al­le­ga­tions

5 years ago
People

Ab­b­Vie ac­cus­es ri­val of steal­ing block­buster ‘trade se­crets’ as clock ticks down on biosim­i­lar as­sault

5 years ago
Pharma

Covid-19 roundup: EU cracks down fur­ther on vac­cine ex­ports; Pfiz­er en­ters race for Covid-19 pill

5 years ago
Coronavirus

Tougher reg­u­la­to­ry en­vi­ron­ment for bio­phar­ma? De­bate en­sues

5 years ago
Pharma
FDA+

Ex­clu­sive: An in­dus­try con­sor­tium wants to stan­dard­ize cell track­ing for re­gen­er­a­tive meds. Could that avert a ...

5 years ago
Cell/Gene Tx
Manufacturing

Af­ter spurn­ing Sanofi for di­a­betes dis­ap­point­ment, Zealand nets FDA ap­proval in se­vere hy­po­glycemia

5 years ago
FDA+

Pfiz­er emerges from pan­dem­ic cru­cible with con­fi­dence to go so­lo in tak­ing mR­NA vac­cines be­yond Covid-19

5 years ago
Pharma
Coronavirus

Hear­ing loss spe­cial­ists at Fre­quen­cy pin the blame for PhI­Ia flop on tri­al de­sign — but they could­n't stem a ...

5 years ago
R&D

Step Phar­ma clos­es $41M round to take en­zyme tar­get­ing lead pro­gram in­to ear­ly-stage tri­al for T cell ma­lig­nan­cies

5 years ago
Financing
Cell/Gene Tx

‘A mess across the board’: Sen­ate com­mit­tee kicks off talks on drug pric­ing re­forms

5 years ago
Pharma
FDA+

One of the mas­ter­minds be­hind remde­sivir, Gilead­'s Di­ana Brainard jumps ship to an­tivi­ral T cell play­er AlloVir

5 years ago
People
First page Previous page 717718719720721722723 Next page Last page
A service from the Financial Times